Summary

The global cancer drugs market is primarily driven by the increasing prevalence of various types of cancer among the global population. As per the GLOBOCAN, a report published by the International Agency for Research on Cancer, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally. Therefore, it is estimated that around 28.4 million new cancer cases will be recorded in 2040 across the globe. The most prominent types of cancer include lungs cancer, breast cancer, prostate cancer, and colorectal cancer. Moreover, the rapid developments in the biopharmaceutical market has resulted in the development of various new and innovative drugs that can efficiently target the cancer cells without harming the normal cells. The increased awareness among the population regarding the availability of various advance therapeutics to treat cancer is significantly driving the growth of the global cancer drugs market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, poses significant challenges to healthcare systems globally, necessitating the continuous evolution of therapeutic interventions. Traditional chemotherapy drugs, such as alkylating agents, antimetabolites, and mitotic inhibitors, work by interfering with the cell division process. They target rapidly dividing cells, a characteristic feature of cancer cells, and disrupt their DNA synthesis or mitosis, leading to cell death.

According to the research report "Global Cancer Drug Market Outlook, 2031," published by Bonafide Research, the Global Cancer Drug market was valued at more than USD 194.05 Billion in 2025, and expected to reach a market size of more than USD 343.36 Billion by 2031 with the CAGR of 10.24% from 2026-2031.The injectable segment accounted for the largest market share over the forecast period. The advantages and clinical benefits of injectable oncology drugs such as an availability of a wide range of polymer structures, high chemical versatility, and others, is leading to an increasing preference of healthcare providers and patients toward these drugs. This combined with emphasis of market players on launching medicines in the injectable form, is projected to drive the growth of the segment during the forecast period. For instance, in January 2025, Johnson & Johnson’s injectable therapy of RYBREVANT (amivantamab for injection) in combination with carboplatin and pemetrexed (platinum-based chemotherapy) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib, was approved in Canada. Immunotherapy is reshaping cancer care by harnessing the body’s immune system to fight tumors. Treatments like checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines have shown promising results across multiple cancer types. The ability of immunotherapies to provide durable responses and potential cures drives strong interest and investment. Ongoing clinical trials explore combination therapies and novel immunomodulators, broadening their applicability and enhancing effectiveness, thus fueling growth in the cancer drugs share.


Market Drivers

? Rising Prevalence of Cancer Worldwide: The primary driver of the Global Cancer Drug Market is the increasing incidence of cancer across the globe due to population aging, lifestyle changes, and environmental risk factors such as pollution, poor diet, smoking, and exposure to carcinogens. As the number of cancer patients grows, there is a corresponding rise in demand for effective therapeutic options, including chemotherapy, targeted therapy, immunotherapy, and hormone-based treatments. Governments and healthcare organizations are also prioritizing cancer screening programs and early detection, which further expands the patient pool eligible for treatment. The development of advanced and personalized cancer drugs is supported by substantial investment in oncology research, facilitating improved treatment outcomes and patient survival rates.
? Technological Advancements: Another critical driver is the rapid technological progress in drug discovery and development, including immuno-oncology, targeted therapies, gene therapy, and nanomedicine-based delivery systems. Advances in biotechnology, molecular biology, and bioinformatics have enabled the development of drugs that can selectively target cancer cells while minimizing damage to healthy tissues, thereby improving efficacy and reducing side effects. The integration of artificial intelligence, machine learning, and high-throughput screening in research and clinical trials has accelerated drug development timelines, lowered costs, and increased the success rate of novel compounds entering the market.

Market Challenges

? High Cost of Cancer Drugs: One of the significant challenges in the Global Cancer Drug Market is the high cost of oncology therapies, including targeted drugs, immunotherapies, and biologics. Many patients, especially in developing countries, cannot afford prolonged treatment regimens, and insurance coverage may be limited, leading to reduced accessibility. The high cost also creates pressure on healthcare systems, governments, and private payers, limiting adoption in price-sensitive markets. Moreover, research and development expenses for novel drugs, including lengthy clinical trials and regulatory approvals, contribute to the pricing challenges, which may hinder market penetration despite growing patient demand.
? Stringent Regulatory Environment: Cancer drug development is highly regulated, requiring rigorous clinical testing, safety evaluation, and compliance with international guidelines. The lengthy approval process by agencies such as the FDA, EMA, and other regional regulatory authorities delays the launch of new drugs, increases costs, and creates uncertainty for manufacturers. Regulatory hurdles for combination therapies, biosimilars, and novel biologics further complicate market entry, limiting innovation speed and affecting overall growth. Companies must navigate complex intellectual property issues, pharmacovigilance requirements, and post-marketing surveillance obligations, which can be resource-intensive.

Market Trends

? Growth of Immunotherapy: A notable trend in the cancer drug market is the increasing adoption of immunotherapies and targeted therapies. Drugs such as checkpoint inhibitors, CAR-T therapies, monoclonal antibodies, and small molecule inhibitors are gaining popularity due to their ability to provide personalized, effective treatment with fewer side effects. Pharmaceutical companies are heavily investing in R&D for these next-generation therapies, which has shifted the focus from conventional chemotherapy to more precise, biologically-driven treatments.
? Expansion in Emerging Markets: Another trend is the expansion of cancer drug markets in emerging economies due to improving healthcare infrastructure, rising awareness, and increasing insurance penetration. Telemedicine platforms, digital health tools, and AI-driven diagnostic solutions are being integrated to support early detection, patient monitoring, and treatment adherence, creating new opportunities for drug adoption. Pharmaceutical companies are also forming partnerships with hospitals, research institutes, and government programs to enhance market access and distribution in regions with growing patient populations.


Targeted therapy is the largest segment in the Global Cancer Drug Market because it selectively attacks cancer cells based on specific molecular markers, offering higher efficacy and better patient outcomes compared to conventional chemotherapy.

Unlike conventional therapies that affect both healthy and cancerous cells, targeted therapies interfere with specific proteins, enzymes, or pathways critical to tumor growth and survival, which results in improved treatment efficacy and fewer adverse effects. This precision-driven approach allows clinicians to design personalized treatment plans, enhancing patient response rates and increasing overall survival. In enterprise monitoring contexts, targeted therapies benefit from advanced diagnostic tools, including genomic sequencing, biomarker identification, and molecular profiling, which provide real-time insights into patient-specific tumor characteristics and treatment effectiveness. Pharmaceutical companies and healthcare providers leverage enterprise monitoring platforms to track patient response, adverse reactions, and dosage optimization, ensuring compliance with treatment protocols and improving operational efficiency in oncology care. The growth of targeted therapies is also propelled by regulatory support and approval incentives from agencies such as the United States Food and Drug Administration, the European Medicines Agency, and other regional authorities, which have accelerated the approval of drugs with demonstrated efficacy against specific cancer mutations. Moreover, the expanding pipeline of targeted therapy drugs covering a wide range of cancers including breast, lung, colorectal, and hematologic malignancies has further strengthened the market position of this segment.

Breast cancer is the largest indication in the Global Cancer Drug Market because it has a high prevalence worldwide and benefits significantly from advances in early detection and personalized treatment approaches, driving sustained demand for oncology drugs.

The high incidence, combined with increasing awareness, routine screening programs, and early detection initiatives, has expanded the patient population eligible for pharmaceutical interventions. Early diagnosis allows for timely administration of advanced therapies, including targeted treatments, hormone therapies, and combination regimens, which improve patient survival rates and reduce disease progression. In the context of enterprise monitoring, breast cancer treatment programs rely on digital platforms and clinical monitoring tools to track patient response, adherence to therapy, side effects, and progression-free survival, providing healthcare providers and pharmaceutical companies with valuable real-time data to optimize care and ensure regulatory compliance. The market growth is further supported by continuous innovation in breast cancer therapeutics, including monoclonal antibodies, small molecule inhibitors, CDK4/6 inhibitors, and immunotherapies, which target specific molecular subtypes of breast cancer such as HER2-positive, estrogen receptor-positive, and triple-negative variants. Enterprise monitoring systems integrate diagnostic data, treatment schedules, and patient-reported outcomes to enable precision oncology approaches, ensuring that therapies are tailored to individual tumor biology and patient needs. Additionally, regulatory agencies like the United States Food and Drug Administration and the European Medicines Agency have approved numerous breast cancer drugs based on strong clinical efficacy and safety profiles, facilitating broader market access and adoption.

Injectable drugs are the largest segment in the Global Cancer Drug Market because they allow direct delivery of active agents into the bloodstream or tumor site and suitability for complex biologics and targeted therapies.

Unlike oral medications, injectables bypass the gastrointestinal tract, avoiding issues related to absorption variability, first-pass metabolism, and reduced bioavailability, which is crucial for maintaining therapeutic efficacy in oncology patients. Enterprise monitoring systems play an essential role in managing injectable cancer treatments by tracking dosing schedules, patient responses, infusion durations, adverse reactions, and overall treatment adherence, which helps healthcare providers optimize therapy outcomes and ensure compliance with treatment protocols. Injectable drugs are particularly important for therapies with narrow therapeutic windows, where precise control over plasma concentrations is required to maximize effectiveness while minimizing toxicity. The growth of injectable cancer drugs is further accelerated by advances in formulation technologies, including liposomal encapsulation, nanoparticle carriers, and subcutaneous delivery systems, which enhance drug stability, bioavailability, and patient convenience. Regulatory approvals from authorities such as the United States Food and Drug Administration and the European Medicines Agency have favored injectable formulations for high-efficacy biologics, immunotherapies, and combination regimens, contributing to their widespread adoption in clinical oncology. Pharmaceutical companies increasingly focus on developing injectable therapies because they can be integrated with enterprise monitoring platforms that collect real-time data on infusion rates, side effects, and biomarker responses, enabling clinicians to tailor treatments to individual patient needs. Injectable administration is also preferred for hospital and outpatient oncology settings, where healthcare providers can control treatment conditions, monitor adverse events immediately, and adjust therapy based on dynamic patient responses.

Hospital pharmacies are the largest distribution channel in the Global Cancer Drug Market because they provide direct access to oncology patients, ensure proper handling and storage of complex therapies, and enable integrated monitoring of treatment administration and outcomes.

Enterprise monitoring systems play a critical role in hospital pharmacy operations by tracking inventory levels, monitoring drug expiration dates, verifying patient-specific prescriptions, and recording administration details, which enhances patient safety, reduces errors, and ensures regulatory compliance. Hospital pharmacies are equipped to manage cold chain storage for temperature-sensitive biologics and maintain controlled environments for handling cytotoxic agents, which is essential for preserving drug efficacy and minimizing degradation. The integration of digital monitoring and automated dispensing systems enables hospital pharmacies to maintain real-time visibility into drug usage patterns, optimize stock management, and prevent shortages, which is particularly important for high-cost oncology therapies. Regulatory frameworks in key markets, including the United States, Europe, and Asia-Pacific, mandate that certain cancer drugs be dispensed through hospital-based facilities due to safety, administration complexity, and risk of adverse reactions, further reinforcing the dominance of hospital pharmacies as a distribution channel. Additionally, hospital pharmacies facilitate patient adherence by coordinating treatment schedules, supporting infusion or injection sessions, and integrating with electronic health records to monitor therapeutic outcomes and side effects, providing a feedback loop for clinicians to adjust treatment protocols. Collaborations between pharmaceutical manufacturers and hospital networks also support training, patient education, and clinical trials, enabling hospitals to serve as both treatment and research hubs. The growing trend of personalized medicine and targeted therapies has increased the complexity of cancer treatment regimens, which requires the controlled environment, clinical oversight, and specialized storage provided by hospital pharmacies.


North America is leading the Global Cancer Drug Market due to its advanced healthcare infrastructure, strong research and development ecosystem and early adoption of innovative therapies supported by favorable regulatory frameworks.

Enterprise monitoring systems are widely deployed in North American healthcare facilities to track patient outcomes, manage complex treatment regimens, optimize inventory and drug administration, and ensure compliance with regulatory and safety standards. The strong prevalence of cancer, including breast, lung, colorectal, and hematologic malignancies, creates a large patient population requiring diverse treatment options, which drives demand for both traditional chemotherapies and innovative targeted therapies, immunotherapies, and combination regimens. North America also benefits from a robust pharmaceutical and biotechnology research and development ecosystem, with significant investments in clinical trials, drug discovery, and precision medicine initiatives. Major oncology companies, research institutes, and hospitals collaborate extensively to accelerate the development and approval of new cancer drugs, and enterprise monitoring technologies enhance these efforts by providing real-time patient data, biomarker analysis, and treatment response tracking. The regulatory environment in North America is highly supportive of oncology innovation, with agencies such as the United States Food and Drug Administration offering accelerated approval pathways, breakthrough therapy designations, and priority review programs for drugs that demonstrate significant clinical benefit. These regulatory incentives reduce the time to market for novel therapies, increase investor confidence, and encourage continuous innovation in cancer treatment. Additionally, high healthcare spending, comprehensive insurance coverage, and reimbursement policies for oncology drugs in North America enable patients to access expensive but life-saving treatments, further fueling market growth.


? August 2025: GlaxoSmithKline launched two precision therapies, Jemperli and Zejula, in India for treating gynaecological cancers, emphasizing its entry into the oncology market.
? August 2025: N-Power Medicine launches the ProECA platform to innovate oncology drug development, reducing patient enrollment by 50%, shortening trials by 6-12 months, and cutting costs significantly.
? April 2025: Researchers in Melbourne launched a world-first clinical trial, hailed as a ‘game-changer’ for its potential to transform bowel cancer treatment. Based on groundbreaking WEHI research, the trial is the first to investigate whether doctors can accurately predict a patient’s response to specific drugs before starting treatment.
? February 2025: The World Health Organization (WHO) has launched a new platform to deliver free cancer medicines to thousands of children in low- and middle-income countries. WHO began the initiative by providing the first batch of medicines to Mongolia and Uzbekistan.
? May 2024: the FDA approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).
? May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) received accelerated approval from the Food and Drug Administration, for extended-stage small cell lung cancer (ES-SCLC) with disease progression during or following platinum-based chemotherapy


Considered in this report
? Historic Year: 2020
? Base year: 2025
? Estimated year: 2026
? Forecast year: 2031

Aspects covered in this report
? Cancer Drug Market with its value and forecast along with its segments
? Various drivers and challenges
? On-going trends and developments
? Top profiled companies
? Strategic recommendation

By Therapy Type
? Chemotherapy
? Targeted Therapy
? Immunotherapy
? Hormonal Therapy
? Other Treatment Types
By Indication
? Breast Cancer
? Lung Cancer (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
? Colorectal Cancer
? Prostate Cancer
? Blood Cancers (Leukemia, Lymphoma, Multiple Myeloma))
? cervical cancer
? Stomach/ Gastric Cancer
? Others (Liver Cancer ,Kidney Cancer (Renal Cell Carcinoma) , ovarian Cancer, Bladder Cancer, Skin Cancer, Brain tumor, Thyroid Cancer )
By Route of Administration
? Oral
? Injectable
By Distribution Channel
? Hospital Pharmacies
? Retail Pharmacies / Drug Stores
? Online Pharmacies


***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents

Table of Content

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global Cancer Drug Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Therapy Type
6.5. Market Size and Forecast, By Indication
6.6. Market Size and Forecast, By Route of Administration
6.7. Market Size and Forecast, By Distribution Channel
7. North America Cancer Drug Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Therapy Type
7.4. Market Size and Forecast, By Indication
7.5. Market Size and Forecast, By Route of Administration
7.6. Market Size and Forecast, By Distribution Channel
7.7. United States Cancer Drug Market Outlook
7.7.1. Market Size by Value
7.7.2. Market Size and Forecast By Therapy Type
7.7.3. Market Size and Forecast By Indication
7.7.4. Market Size and Forecast By Route of Administration
7.7.5. Market Size and Forecast By Distribution Channel
7.8. Canada Cancer Drug Market Outlook
7.8.1. Market Size by Value
7.8.2. Market Size and Forecast By Therapy Type
7.8.3. Market Size and Forecast By Indication
7.8.4. Market Size and Forecast By Route of Administration
7.8.5. Market Size and Forecast By Distribution Channel
7.9. Mexico Cancer Drug Market Outlook
7.9.1. Market Size by Value
7.9.2. Market Size and Forecast By Therapy Type
7.9.3. Market Size and Forecast By Indication
7.9.4. Market Size and Forecast By Route of Administration
7.9.5. Market Size and Forecast By Distribution Channel
8. Europe Cancer Drug Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Therapy Type
8.4. Market Size and Forecast, By Indication
8.5. Market Size and Forecast, By Route of Administration
8.6. Market Size and Forecast, By Distribution Channel
8.7. Germany Cancer Drug Market Outlook
8.7.1. Market Size by Value
8.7.2. Market Size and Forecast By Therapy Type
8.7.3. Market Size and Forecast By Indication
8.7.4. Market Size and Forecast By Route of Administration
8.7.5. Market Size and Forecast By Distribution Channel
8.8. United Kingdom (UK) Cancer Drug Market Outlook
8.8.1. Market Size by Value
8.8.2. Market Size and Forecast By Therapy Type
8.8.3. Market Size and Forecast By Indication
8.8.4. Market Size and Forecast By Route of Administration
8.8.5. Market Size and Forecast By Distribution Channel
8.9. France Cancer Drug Market Outlook
8.9.1. Market Size by Value
8.9.2. Market Size and Forecast By Therapy Type
8.9.3. Market Size and Forecast By Indication
8.9.4. Market Size and Forecast By Route of Administration
8.9.5. Market Size and Forecast By Distribution Channel
8.10. Italy Cancer Drug Market Outlook
8.10.1. Market Size by Value
8.10.2. Market Size and Forecast By Therapy Type
8.10.3. Market Size and Forecast By Indication
8.10.4. Market Size and Forecast By Route of Administration
8.10.5. Market Size and Forecast By Distribution Channel
8.11. Spain Cancer Drug Market Outlook
8.11.1. Market Size by Value
8.11.2. Market Size and Forecast By Therapy Type
8.11.3. Market Size and Forecast By Indication
8.11.4. Market Size and Forecast By Route of Administration
8.11.5. Market Size and Forecast By Distribution Channel
8.12. Russia Cancer Drug Market Outlook
8.12.1. Market Size by Value
8.12.2. Market Size and Forecast By Therapy Type
8.12.3. Market Size and Forecast By Indication
8.12.4. Market Size and Forecast By Route of Administration
8.12.5. Market Size and Forecast By Distribution Channel
9. Asia-Pacific Cancer Drug Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Therapy Type
9.4. Market Size and Forecast, By Indication
9.5. Market Size and Forecast, By Route of Administration
9.6. Market Size and Forecast, By Distribution Channel
9.7. China Cancer Drug Market Outlook
9.7.1. Market Size by Value
9.7.2. Market Size and Forecast By Therapy Type
9.7.3. Market Size and Forecast By Indication
9.7.4. Market Size and Forecast By Route of Administration
9.7.5. Market Size and Forecast By Distribution Channel
9.8. Japan Cancer Drug Market Outlook
9.8.1. Market Size by Value
9.8.2. Market Size and Forecast By Therapy Type
9.8.3. Market Size and Forecast By Indication
9.8.4. Market Size and Forecast By Route of Administration
9.8.5. Market Size and Forecast By Distribution Channel
9.9. India Cancer Drug Market Outlook
9.9.1. Market Size by Value
9.9.2. Market Size and Forecast By Therapy Type
9.9.3. Market Size and Forecast By Indication
9.9.4. Market Size and Forecast By Route of Administration
9.9.5. Market Size and Forecast By Distribution Channel
9.10. Australia Cancer Drug Market Outlook
9.10.1. Market Size by Value
9.10.2. Market Size and Forecast By Therapy Type
9.10.3. Market Size and Forecast By Indication
9.10.4. Market Size and Forecast By Route of Administration
9.10.5. Market Size and Forecast By Distribution Channel
9.11. South Korea Cancer Drug Market Outlook
9.11.1. Market Size by Value
9.11.2. Market Size and Forecast By Therapy Type
9.11.3. Market Size and Forecast By Indication
9.11.4. Market Size and Forecast By Route of Administration
9.11.5. Market Size and Forecast By Distribution Channel
10. South America Cancer Drug Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Therapy Type
10.4. Market Size and Forecast, By Indication
10.5. Market Size and Forecast, By Route of Administration
10.6. Market Size and Forecast, By Distribution Channel
10.7. Brazil Cancer Drug Market Outlook
10.7.1. Market Size by Value
10.7.2. Market Size and Forecast By Therapy Type
10.7.3. Market Size and Forecast By Indication
10.7.4. Market Size and Forecast By Route of Administration
10.7.5. Market Size and Forecast By Distribution Channel
10.8. Argentina Cancer Drug Market Outlook
10.8.1. Market Size by Value
10.8.2. Market Size and Forecast By Therapy Type
10.8.3. Market Size and Forecast By Indication
10.8.4. Market Size and Forecast By Route of Administration
10.8.5. Market Size and Forecast By Distribution Channel
10.9. Colombia Cancer Drug Market Outlook
10.9.1. Market Size by Value
10.9.2. Market Size and Forecast By Therapy Type
10.9.3. Market Size and Forecast By Indication
10.9.4. Market Size and Forecast By Route of Administration
10.9.5. Market Size and Forecast By Distribution Channel
11. Middle East & Africa Cancer Drug Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Therapy Type
11.4. Market Size and Forecast, By Indication
11.5. Market Size and Forecast, By Route of Administration
11.6. Market Size and Forecast, By Distribution Channel
11.7. United Arab Emirates (UAE) Cancer Drug Market Outlook
11.7.1. Market Size by Value
11.7.2. Market Size and Forecast By Therapy Type
11.7.3. Market Size and Forecast By Indication
11.7.4. Market Size and Forecast By Route of Administration
11.7.5. Market Size and Forecast By Distribution Channel
11.8. Saudi Arabia Cancer Drug Market Outlook
11.8.1. Market Size by Value
11.8.2. Market Size and Forecast By Therapy Type
11.8.3. Market Size and Forecast By Indication
11.8.4. Market Size and Forecast By Route of Administration
11.8.5. Market Size and Forecast By Distribution Channel
11.9. South Africa Cancer Drug Market Outlook
11.9.1. Market Size by Value
11.9.2. Market Size and Forecast By Therapy Type
11.9.3. Market Size and Forecast By Indication
11.9.4. Market Size and Forecast By Route of Administration
11.9.5. Market Size and Forecast By Distribution Channel
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2025
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. Roche Holding AG
12.6.1.1. Company Snapshot
12.6.1.2. Company Overview
12.6.1.3. Financial Highlights
12.6.1.4. Geographic Insights
12.6.1.5. Business Segment & Performance
12.6.1.6. Product Portfolio
12.6.1.7. Key Executives
12.6.1.8. Strategic Moves & Developments
12.6.2. AbbVie Inc.
12.6.3. Novartis AG
12.6.4. Pfizer Inc.
12.6.5. Eli Lilly and Company
12.6.6. AstraZeneca plc
12.6.7. BeOne Medicines
12.6.8. Johnson & Johnson
12.6.9. Amgen Inc.
12.6.10. Takeda Pharmaceutical Company Limited
12.6.11. Astellas Pharma Inc.
12.6.12. Eisai Co., Ltd.
12.6.13. Gilead Sciences, Inc.
12.6.14. Daiichi Sankyo Company, Limited
12.6.15. Regeneron Pharmaceuticals, Inc.
12.6.16. Incyte Corporation
12.6.17. Genmab A/S
12.6.18. Bristol-Myers Squibb Company
12.6.19. Merck & Co., Inc.
12.6.20. Exelixis, Inc.
13. Strategic Recommendations
14. Annexure
14.1. FAQ`s
14.2. Notes
15. Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Figure

Figure 1: Global Cancer Drug Market Size (USD Billion) By Region, 2025 & 2031F
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Cancer Drug Market Share By Region (2025)
Figure 6: North America Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Cancer Drug Market Share By Country (2025)
Figure 8: US Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Cancer Drug Market Share By Country (2025)
Figure 13: Germany Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Cancer Drug Market Share By Country (2025)
Figure 21: China Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Cancer Drug Market Share By Country (2025)
Figure 28: Brazil Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Cancer Drug Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Cancer Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Cancer Drug Market


List of Table

Table 1: Global Cancer Drug Market Snapshot, By Segmentation (2025 & 2031F) (in USD Billion)
Table 2: Influencing Factors for Cancer Drug Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Cancer Drug Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 8: Global Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 9: Global Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 10: Global Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 12: North America Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 13: North America Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 14: North America Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 15: North America Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 17: United States Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 18: United States Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 19: United States Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 20: United States Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 22: Canada Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 23: Canada Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 24: Canada Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 25: Canada Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 27: Mexico Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 28: Mexico Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 29: Mexico Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 30: Mexico Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 32: Europe Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 33: Europe Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 34: Europe Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 35: Europe Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 37: Germany Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 38: Germany Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 39: Germany Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 40: Germany Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 42: United Kingdom (UK) Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 43: United Kingdom (UK) Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 44: United Kingdom (UK) Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 45: United Kingdom (UK) Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 47: France Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 48: France Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 49: France Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 50: France Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 52: Italy Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 53: Italy Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 54: Italy Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 55: Italy Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 57: Spain Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 58: Spain Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 59: Spain Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 60: Spain Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 62: Russia Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 63: Russia Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 64: Russia Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 65: Russia Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 67: Asia-Pacific Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 68: Asia-Pacific Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 69: Asia-Pacific Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 70: Asia-Pacific Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 72: China Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 73: China Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 74: China Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 75: China Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 77: Japan Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 78: Japan Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 79: Japan Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 80: Japan Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 82: India Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 83: India Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 84: India Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 85: India Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 87: Australia Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 88: Australia Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 89: Australia Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 90: Australia Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 92: South Korea Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 93: South Korea Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 94: South Korea Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 95: South Korea Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 97: South America Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 98: South America Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 99: South America Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 100: South America Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 102: Brazil Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 103: Brazil Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 104: Brazil Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 105: Brazil Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 107: Argentina Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 108: Argentina Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 109: Argentina Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 110: Argentina Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 112: Colombia Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 113: Colombia Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 114: Colombia Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 115: Colombia Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 117: Middle East & Africa Cancer Drug Market Size and Forecast, By Therapy Type (2020 to 2031F) (In USD Billion)
Table 118: Middle East & Africa Cancer Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 119: Middle East & Africa Cancer Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 120: Middle East & Africa Cancer Drug Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 122: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 123: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 124: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 125: United Arab Emirates (UAE) Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 127: Saudi Arabia Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 128: Saudi Arabia Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 129: Saudi Arabia Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 130: Saudi Arabia Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 132: South Africa Cancer Drug Market Size and Forecast By Therapy Type (2020 to 2031F) (In USD Billion)
Table 133: South Africa Cancer Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 134: South Africa Cancer Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 135: South Africa Cancer Drug Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 137: Competitive Dashboard of top 5 players, 2025
Table 138: Key Players Market Share Insights and Analysis for Cancer Drug Market 2025